Current Treatment Options in Oncology

, Volume 2, Issue 3, pp 271–283

Bone disease in myeloma

  • James R. Berenson

Opinion statement

The major clinical manifestation of multiple myeloma results from osteolytic bone destruction. The only currently Food and Drug Administration-approved drug for the treatment of the bony complications of multiple myeloma is monthly intravenous pamidronate at a dose of 90 mg infused over 4 hours. Recent studies have shown the safety of 2-hour infusions. A randomized trial comparing pamidronate to placebo continued to show benefits throughout the 21-month trial. Although the duration of therapy has not been firmly determined, it is likely that discontinuation of this drug will be met by enhanced bone loss and an increased risk of bony complications for these patients. Thus, it is recommended that the drug be continued indefinitely. Support for this recommendation also comes from the reduced bone density observed in women with postmenopausal osteoporosis following the withdrawal of bisphosphonate treatment. Recent attempts to give higher doses, more frequent infusions (every 2 weeks or less), or more rapid infusions (1 hour or less) of pamidronate have occasionally been associated with albuminuria and azotemia. These modifications should therefore be avoided. Importantly, the drug can be safely administered at 90 mg monthly to patients with poor renal function. The use of pamidronate for myeloma patients without lytic bone involvement or with Durie-Salmon stages I or II disease has not been evaluated. However, it is recognized that most patients with earlier stages of disease or without lytic bone involvement also develop bony complications. There is no reason to believe that these patients would not benefit from monthly intravenous infusions of pamidronate. The potential antimyeloma effect of this agent is another reason to administer this drug in these types of patients. Thus, it is our practice to administer monthly pamidronate to myeloma patients regardless of stage or bone involvement. However, trials evaluating oral bisphosphonates have produced inconsistent clinical results, probably as a result of the erratic and scanty poor absorption as well as poor oral tolerability of these drugs. Although these oral agents may be useful in some patients, it is impossible to identify which myeloma patients will benefit from orally administered bisphosphonates. The more potent nitrogen-containing bisphosphonate zoledronic acid more effectively reverses hypercalcemia of malignancy than pamidronate, and it appears promising in reducing bone loss in cancer patients. However, its efficacy in preventing skeletal complications is still being evaluated. Many other types of new agents are in early clinical trials, but their efficacy remains unproven at the present time.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Mundy GR, Bertoline DR: Bone destruction and hypercalcemia in plasma cell myeloma. Semin Oncol 1986, 13:291–299.PubMedGoogle Scholar
  2. 2.
    Belch AR, Bergsagel DE, Wilson K, et al.: Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 1991, 9:1397–1402.PubMedGoogle Scholar
  3. 3.
    Kyle RA, Jowsey J, Kelly PJ, et al.: Multiple myeloma bone disease. The comparative effect of sodium fluoride and calcium carbonate or placebo. N Engl J Med 1975, 293:1334–1338.PubMedCrossRefGoogle Scholar
  4. 4.
    Kyle RA: Multiple myeloma, review of 869 cases. Mayo Clin Proc 1975, 50:29–40.PubMedGoogle Scholar
  5. 5.
    Stashenko P, Dewhirst FE, Peros WJ, et al.: Synergistic interactions between interleukin 1, tumor necrosis factor, and lymphotoxin in bone resorption. J Immunol 1987, 138:1464–1468.PubMedGoogle Scholar
  6. 6.
    Mundy GR: Mechanisms of osteolytic bone destruction. Bone 1991, 12(suppl):S1-S6.PubMedCrossRefGoogle Scholar
  7. 7.
    Bataille R, Chappard D, Basle M: Excessive bone resorption in human plasmacytomas: direct induction by tumor cells in vivo. Br J Haematol 1995, 90:721–724.PubMedGoogle Scholar
  8. 8.
    Berenson JR, Lipton A: Bisphosphonates in the treatment of malignant bone disease. Annu Rev Med 1999, 50:237–248. This article reviews clinical trials involving bisphosphonates in the treatment of bone metastases.PubMedCrossRefGoogle Scholar
  9. 9.
    Kanis JA, McCloskey EV, Taube T, et al.: Rationale for the use of bisphosphonates in bone metastases. Bone 1991, 12(suppl):S13-S18.PubMedCrossRefGoogle Scholar
  10. 10.
    Fleisch H: Bisphosphonates: a new class of drugs in diseases of bone and calcium metabolism. In Recent Results in Cancer Research, Vol. 116: Bisphosphonates and Tumor Osteolysis. Edited by Brunner KW, Fleisch H, Senn H-J. Berlin: Springer-Verlag; 1989:12–28.Google Scholar
  11. 11.
    Lahtinen R, Laakso M, Palva I, et al.: Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 1992, 340:1049–1052.PubMedCrossRefGoogle Scholar
  12. 12.
    Man Z, Otero AB, Rendo P, et al.: Use of pamidronate for multiple myeloma osteolytic lesions. Lancet 1990, 335:663.PubMedCrossRefGoogle Scholar
  13. 13.
    Thiebaud D, Leyuraz S, Von Fliedner V, et al.: Treatment of bone metastases from breast cancer and myeloma with pamidronate. Eur J Cancer 1991, 27:37–41.PubMedCrossRefGoogle Scholar
  14. 14.
    Purohit OP, Anthony C, Radstone CR, et al.: High-dose intravenous pamidronate for metastatic bone pain. Br J Cancer 1994, 70:554–558.PubMedGoogle Scholar
  15. 15.
    van Holten-Verzantvoort AATM, Kroon HM, Bijvoet OLM, et al.: Palliative treatment in patients with bone metastases from breast cancer. J Clin Oncol 1993, 11:491–498.PubMedGoogle Scholar
  16. 16.
    McCloskey EV, MacLennan CM, Drayson MT, et al.:A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Br J Haematol 1998, 101:317–325.CrossRefGoogle Scholar
  17. 17.
    Heim ME, Clemens MR, Queisser W, et al.:Prospective randomized trial of dichloromethylene bisphosphonate (clodronate) in patients with multiple myeloma requiring treatment. A multicenter study. Onkologie 1995, 18:439–448.CrossRefGoogle Scholar
  18. 18.
    Brincker H, Westin J, Abildgaard U, et al.: Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Br J Haematol 1998, 101:280–286.PubMedCrossRefGoogle Scholar
  19. 19.
    Berenson JR, Lichtenstein A, Porter L, et al.: Efficacy of pamidronate in reducing the skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996, 334:488–493.PubMedCrossRefGoogle Scholar
  20. 20.
    Berenson J, Lichtenstein A, Porter L, et al.: Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998, 16:593–602.PubMedGoogle Scholar
  21. 21.
    Rowell NP, Tobias JS: The role of radiotherapy in the management of multiple myeloma. Blood Rev 1991, 5:84–89.PubMedCrossRefGoogle Scholar
  22. 22.
    Rostom AY: A review of the place of radiotherapy in myeloma with emphasis on whole body irradiation. Hematol Oncol 1988, 6:193–198.PubMedCrossRefGoogle Scholar
  23. 23.
    Giles FJ, McSweeney EN, Richards JDM, et al.:Prospective randomised study of double hemibody irradiation with and without subsequent maintenance recombinant alpha 2b interferon on survival in patients with relapsed multiple myeloma. Eur J Cancer 1992, 28A:1392–1395.PubMedCrossRefGoogle Scholar
  24. 24.
    Giralt S, Champlin R, Goodman M, et al.: Preliminary results of a phase I/II study of multiple myeloma (MM) patients treated with 166holmium-DOTMP in combination with high dose melphalan +/- total body irradiation (TBI) with autologous stem cell transplant (ASCT). Blood 2000, 96:558a.Google Scholar
  25. 25.
    Cohen HJ, Silberman HR, Tornyos K, et al.: Comparison of two long-term chemotherapy regimens, with or without agents to modify skeletal repair, in multiple myeloma. Blood 1984, 63:639–648.PubMedGoogle Scholar
  26. 26.
    Acute Leukemia Group B, Eastern Cooperative Oncology Group B: Ineffectiveness of fluoride therapy in multiple myeloma. N Engl J Med 1972, 286:1283–1288.CrossRefGoogle Scholar
  27. 27.
    Warrell RP, Lovett D, Dilmanian A, et al.: Low-dose gallium nitrate for prevention of osteolysis in myeloma: results of a pilot randomized study. J Clin Oncol 1993, 11:2443–2450.PubMedGoogle Scholar
  28. 28.
    Major P, Lortholary A, Hon J, et al.: Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001, 19:558–567. This clinical trial provides the first clear data showing the superiority of a third-generation bisphosphonate over pamidronate.PubMedGoogle Scholar
  29. 29.
    Fleisch H: Bisphosphonates: mechanisms of action. Endocr Rev 1998, 19:80–100. An excellent review of the mechanisms of action of bisphosphonates.PubMedCrossRefGoogle Scholar
  30. 30.
    Aparicio A, Gardner A, Tu Y, et al.: In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 1998, 12:220–229.PubMedCrossRefGoogle Scholar
  31. 31.
    Shipman CM, Croucher PI, Russell GG, et al.: The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 1998, 58:5294–5297.PubMedGoogle Scholar
  32. 32.
    Luckman SP, Hughes DE, Coxon FP, et al.: Nitrogencontaining bisphosphonates inhibit the mevalonic pathway and prevent post-translational prenylation of GTP-binding proteins, including ras. J Bone Miner Res 1998, 13:581–589.PubMedCrossRefGoogle Scholar
  33. 33.
    Reinholz GG, Getz B, Pederson L, et al.: Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 2000, 60:6001–6007.PubMedGoogle Scholar
  34. 34.
    Savage AD, Belson DJ, Vescio RA, et al.: Pamidronate reduces IL-6 production by bone marrow stroma from myeloma patients. Blood 1996, 88:105a.Google Scholar
  35. 35.
    Derenne S, Amiot M, Barille S, et al.: Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMp-1 by the tumoral environment. J Bone Miner Res 1999, 14:2048–2056.PubMedCrossRefGoogle Scholar
  36. 36.
    Giuliani N, Pedrazzoni M, Passeri G, et al.: Bisphosphonates inhibit IL-6 production by human osteoblast-like cells. Scand J Rheumatol 1998, 27:38.PubMedCrossRefGoogle Scholar
  37. 37.
    Wood J, Schnell C, Green J: Zoledronic acid (Zometa), a potent inhibitor of bone resorption, inhibits proliferation and induces apoptosis in human endothelial cells in vitro and is anti-angiogenic in a murine growth factor implant model. Proc Am Soc Clin Oncol 2000, 19:664a.Google Scholar
  38. 38.
    Singhal S, Mehta J, Desikan R, et al.: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999, 341:1565–1561.PubMedCrossRefGoogle Scholar
  39. 39.
    Kunzmann V, Bauer E, Feurle J, et al.: Stimulation of gdT cells by aminobisphosphonate and induction of antiplasma cell activity in multiple myeloma. Blood 2000, 96:384–392.PubMedGoogle Scholar
  40. 40.
    Radl J, Croese JW, Zurcher C, et al.: Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma. Cancer 1985, 55:1030–1040.PubMedCrossRefGoogle Scholar
  41. 41.
    Yaccoby S, Barlogie B, Epstein J: Pamidronate inhibits growth of myeloma in vivo in the SCID-hu system. Blood 1998, 92:106a.Google Scholar
  42. 42.
    Yaccoby S, Pearse R, Epstein J, et al.: Reciprocal relationship between myeloma-induced changes in the bone marrow microenvironment and myeloma cell growth. Blood 2000, 96:549a.Google Scholar
  43. 43.
    Dallas SL, Garrett IR, Oyajobi BO, et al.: Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease. Blood 1999, 93:1697–1706.PubMedGoogle Scholar
  44. 44.
    Delmas PD, Charhon S, Chapuy MC, et al.: Long-term effects of dichloromethylene diphosphonate (C12MDP) on skeletal lesions in multiple myeloma. Metabolic Bone Dis Related Res 1982, 4:163–168.CrossRefGoogle Scholar
  45. 45.
    Merlini G, Parrinello GA, Piccinini L, et al.: Long-term effects of parenteral dichloromethylene bisphosphonate (C12MDP) on bone disease of myeloma patients treated with chemotherapy. Hematol Oncol 1990, 90:2127–2147.Google Scholar
  46. 46.
    Ravn P, Bidstrup M, Wasnich RD, et al.: Alendronate and estrogen-progestin the long-term prevention of bone loss: four-year results from the early postmenopausal osteoporosis intervention cohort study. A randomized, controlled trial. Ann Intern Med 1999, 131:935–942.PubMedGoogle Scholar
  47. 47.
    Berenson J, Rosen L, Vescio R, et al.: Pharmacokinetics of pamidronate disodium in cancer patients with normal and impaired renal dysfunction. J Clin Pharmacol 1997, 37:285–290.PubMedGoogle Scholar
  48. 48.
    Muhlbacher RC, Bauss F, Schenk R, et al.: BM.21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 1991, 6:1003.CrossRefGoogle Scholar
  49. 49.
    Green JR, Muller K, Jaeggi KA: Preclinical pharmacology of CGP 42’446, a new, potent heterocyclic bisphosphonate compound. J Bone Miner Res 1994, 9:745–750.PubMedGoogle Scholar
  50. 50.
    Percherstorfer M, Herrmann Z, Body JJ, et al.: Randomized phase II trial comparing different doses of the bisphosphonate idbandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol 1996, 14:268–276.Google Scholar
  51. 51.
    Body JJ, Lortholary A, Romieu G, et al.: A dose-finding study of Zoledronate in hypercalcemic cancer patients. J Bone Miner Res 1999, 14:1551–1661.CrossRefGoogle Scholar
  52. 52.
    Berenson J, Vescio R, Henick K, et al.: A phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease. Cancer 2001, 91:144–154.PubMedCrossRefGoogle Scholar
  53. 53.
    Berenson J, Vescio R, Rosen L, et al.: A phase I doseranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. Clin Cancer Res 2001, In press.Google Scholar
  54. 54.
    Berenson J, Rosen LS, Howell A, et al.: Zoledronic acid reduces skeletal related events in patients with osteolytic metastases: a double-blind, randomized dose-response study. Cancer 2001, In press.Google Scholar
  55. 55.
    Fontana A, Hermann Z, Menssen HD, et al.: Effects of intravenous ibandronate therapy on skeletal related events (SRE) and survival inpatients with advanced multiple myeloma. Blood 1998, 92:106a.Google Scholar
  56. 56.
    Hofbauer LC: Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism. Soc Eur J Endocrinol 1999, 141:195–210. This article provides a review of the RANK, RANK ligand, and OPG molecules.CrossRefGoogle Scholar
  57. 57.
    Altamirano CV, Ma HJ, Parker KM, et al.: RANKL is expressed in malignant multiple myeloma (MM) cell lines. Blood 2000, 96:365a.Google Scholar
  58. 58.
    Shipman CM, Holen I, Lippitt JM, et al.: Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL. Blood 2000, 96:360a.Google Scholar
  59. 59.
    Capparelli C, Kostenuik PJ, Morony S, et al.:Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Res 2000, 60:783–787.PubMedGoogle Scholar
  60. 60.
    Honore P, Luger NM, Sabino MAC, et al.: Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 2000, 6:521–528.PubMedCrossRefGoogle Scholar
  61. 61.
    Pearse RN, Sordillo EM, Yaccoby S, et al.: Administration of TRANCE-antagonist TR-Fc limits myeloma-induced bone destruction. Blood 2000, 96:549a.Google Scholar
  62. 62.
    Iotsova V, Caamano J, Loy J, et al.: Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med 1997, 11:1285–1289.CrossRefGoogle Scholar
  63. 63.
    Andela VB, Schwarz EM, Puzas E, et al.: Tumor metastasis and the reciprocal regulation of prometastatic and antimetastatic factors by nuclear factor kB. Cancer Res 2000, 60:6557–6562.PubMedGoogle Scholar
  64. 64.
    Stinchcombe TE, Mitchell BS, Depcik-Smith N, et al.:PS-341 is active in multiple myeloma: preliminary report of a phase I trial of the proteasome inhibitor PS-341 in patients with hematologic malignancies. Blood 2000, 96:516a.Google Scholar
  65. 65.
    Mundy G, Garrett R, Harris S, et al.: Stimulation of bone formation in vitro and in rodents by statins. Science 1999, 286:1946–1949. This preclinical study suggests the possible usefulness of statins in increasing bone density.PubMedCrossRefGoogle Scholar
  66. 66.
    Service RF: Tissue engineers build new bone. Science 2000, 289:1498–1499.PubMedCrossRefGoogle Scholar
  67. 67.
    Engleman VW, Nickols GA, Ross FP, et al.: A peptidomimetic antagonist of the avb3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. J Clin Invest 1997, 99:2284–2292.PubMedGoogle Scholar
  68. 68.
    Carron CP, Myer DM, Engleman VW, et al.: Peptidomimetic antagonist of aVb3 inhibit bone resorption by inhibiting osteoclast bone resorptive activity, not osteoclast adhesion to bone. J Endocrinol 2000, 165:587–598.PubMedCrossRefGoogle Scholar
  69. 69.
    Brooks PC, Clark RA, Cheresh DA: Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994, 264:569.PubMedCrossRefGoogle Scholar
  70. 70.
    Brooks PC, Stromblad S, Klemke R, et al.: Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995, 96:1815.PubMedGoogle Scholar
  71. 71.
    Ray J, Stetler-Stevenson W: Gelatinase A activity directly modulates melanoma cell adhesion and spreading. EMBO J 1995, 14:908.PubMedGoogle Scholar
  72. 72.
    Yoneda T, Sasaki A, Dunstan C, et al.: Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 1997, 99:2509–2517.PubMedCrossRefGoogle Scholar
  73. 73.
    Vacca A, Ribatta D, Preta M, et al.: Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999, 93:3064–3073.PubMedGoogle Scholar
  74. 74.
    Silletti S, Kessler T, Goldberg J, et al.: Disruption of matrix metalloproteinase 2 binding to integrin aVb3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc Nat Acad Sci U S A 2001, 98:119–124.CrossRefGoogle Scholar
  75. 75.
    Schwartzberg PL, Xing L, Hoffmann O, et al.: Rescue of osteoclast function by transgenic expression of kinase-deficient Src in src-/-mutant mice. Genes Dev 1997, 11:2835–2834.PubMedGoogle Scholar

Copyright information

© Current Science Inc 2001

Authors and Affiliations

  • James R. Berenson
    • 1
  1. 1.Cedars-Sinai Medical CenterUniversity of California, Los Angeles School of MedicineCALos AngelesUSA

Personalised recommendations